The End-Stage Renal Disease Symptom Checklist – Transplantation Module (ESRD-SCL®) was developed to assess the specific physical and psychological quality of life of renal transplant recipients, with a special focus on side effects of immune system suppression therapy. A list of potentially relevant items was administered to 458 transplant recipients. The symptoms present in >20% of patients were chosen, and factor analysis was used to create the final questionnaire which consists of 43 items in six dimensions: (1) limited physical capacity (10 items; internal consistency: Cronbach’s α = 0.85); (2) limited cognitive capacity (8 items, α = 0.82); (3) cardiac and renal dysfunction (7 items, α = 0.76); (4) side effects of corticosteroids (5 items, α = 0.77); (5) increased growth of gum and hair (5 items, α = 0.78), and (6) transplantation-associated psychological distress (8 items, α = 0.80). All questions are scored on a five-point Likert scale. Validity was demonstrated in correlation with corresponding SF-36 scales and in a stepwise hierarchical regression model predicting the subscales of the ESRD-SCL by sociodemographic and medical data. The ESRD-SCL was found to have adequate reliability, test-retest correlations in a subsample of 88 stable patients after 1 year, and construct validity.

Keywords:
Renal transplantation, Chronic renal failure, Quality of life, Disease-specific questionnaire
1.
Aaronson NK: Assessing the quality of life of patients in cancer clinical trials: Common problems and common sense solutions. Eur J Cancer 1992;28:1304–1307.
2.
Kaplan De-Nour A, Brickman AL: Determining quality of life in the renal replacement therapies; in Spilker B (ed): Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia, Lippincott-Raven, 1996, pp 953–960.
3.
Bremer BA: Absence of control over health and the psychological adjustment to end-stage renal disease. Anal Behav Med 1995;17:227–233.
4.
Evans RW, Manninen DL, Garrison LP, Hart LG, Blagg CR, Gutman RA, Hull AR, Lowrie EG: The quality of life of patients with end-stage renal disease. N Engl J Med 1985;312:553–563.
5.
Parfrey PS, Vavasour H, Bullock M, Henry S, Harnett J, Gault MH: Development of a health questionnaire specific for end-stage renal disease. Nephron 1989;52:20–28.
6.
Park H, Bang WR, Kim SJ, Kim ST, Lee JS, Kim S, Han JS: Quality of life of ESRD patients: Development of a tool and comparison between transplant and dialysis patients. Transplant Proc 1992;24:1435–1437.
7.
Barrett BJ, Vavasour HM, Major A, Parfrey PS: Clinical and psychological correlates of somatic symptoms in patients on dialysis. Nephron 1990;55:10–15.
8.
Craven J, Littlefield C, Rodin G, Murray M: The end-stage renal disease severity index (ESRD-SI). Psychol Med 1991;21:237–243.
9.
Laupacis A, Wong C, Churchill D, The Canadian Erythropoietin Study Group: The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythropoietin. Control Clin Trials 1991;12:168–179.
10.
Hays RD, Kallich JD, Mapes DL, Coons SJ, Catrer WB: Development of the Kidney Disease Quality of Life (KDQOLTM) Instrument. Qual Life Res 1994;3:329–338.
11.
Laupacis A, Pus N, Mairhead N, Wong C, Ferguson B, Keown P: Disease-specific questionnaire for patients with a renal transplant. Nephron 1993;64:226–231.
12.
Derogatis LR: SCL-90-R, Administration, Scoring & Procedures Manual-II for the R(evised) Version and Other Instruments of the Psychopathology Rating Scale Series. Townson, Clinical Psychometric Research, Inc., 1992.
13.
Franke GH: Die Symptom-Checkliste von Derogatis – deutsche Version (The Symptom-Checklist of Derogatis – Manual of the German version). Göttingen, Beltz, 1995.
14.
Ware JE, Sherbourne CD: The MOS 36-item short form health survey (SF-36). Med Care 1992;30:473–483.
15.
Bullinger M: German translation and psychometric testing of the SF-36 Health Survey: Preliminary results from the IQOLA Project. Soc Sci Med 1995;41:1359–1366.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.